{"entity":{"id":"nct05605509","kind":"trial","name":"RP-6306 in Patients With Advanced Cancer","aka":[],"tldr":"A phase 2 trial of Lunresertib run by Canadian Cancer Trials Group, completed.","summary":"RP-6306 in Patients With Advanced Cancer is a phase 2 interventional study registered as NCT05605509 by Canadian Cancer Trials Group, with 28 participants enrolled, started 2023-05-24. Conditions recorded: Advanced Cancer. Interventions recorded: RP-6306, Gemcitabine, FOLFIRI Protocol, Trastuzumab and RP-3500.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT05605509","url":"https://clinicaltrials.gov/study/NCT05605509"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["lunresertib"],"companies":["repare-therapeutics","debiopharm"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05605509","phase":"2","setting":"A Phase II Study of RP-6306 in Patients With Advanced Cancer","sponsor":"Canadian Cancer Trials Group","enrolled":28,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05605509/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"lunresertib","kind":"drug","name":"Lunresertib","route":"/drugs/lunresertib/"}],"company":[{"id":"debiopharm","kind":"company","name":"Debiopharm","route":"/companies/debiopharm/"},{"id":"repare-therapeutics","kind":"company","name":"Repare Therapeutics","route":"/companies/repare-therapeutics/"}]}}